Intellia Therapeutics, Inc., a genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, has moved to its new lab facilities in Cambridge, MA.
 
“The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Nessan Bermingham, Ph.D., chief executive officer and founder, Intellia Therapeutics. “To reach our goals, we continue to recruit top talent and ensure our quality workforce has the appropriate facilities and tools necessary to translate CRISPR/Cas9 into life-transforming products.”
 
The new headquarters was specifically designed to accommodate the company’s growing R&D, operations teams and administrative staff. Intellia will maintain operations at its current facility at 130 Brookline Street in Cambridge. The new facility increases Intellia’s total lab and office space from the current 15,000 sq.-ft. to more than 80,000 sq.-ft. and will allow the company to double its team to more than 200 employees.
 
“Intellia Therapeutics’ new headquarters is a testament to the potential of the company and the promise their transformative gene therapy represents to patients and their families living with severe and life-threatening diseases,” said Governor Charlie Baker. “The innovations coming out of Massachusetts have a dramatic impact across the global life sciences sector, and we look forward to Intellia Therapeutics’ continued growth and contributions to this field.”